Skip to main content

Drug Updates

Lenvima (Lenvatinib), a Multireceptor Tyrosine Kinase Inhibitor, Approved by the FDA for the Treatment of Patients with Differentiated Thyroid Cancer

By Loretta Fala

April 2015, Vol 5, No 3

Cyramza (Ramucirumab) Approved for the Treatment of Advanced Gastric Cancer and Metastatic Non–Small-Cell Lung Cancer

By Loretta Fala

March 2015, Vol 5, No 2

Nivolumab (Opdivo): Second PD-1 Inhibitor Receives FDA Approval for Unresectable or Metastatic Melanoma

February 2015, Vol 5, No 1

Zydelig (Idelalisib): First-in-Class PI3 Kinase Inhibitor Approved by the FDA for the Treatment of 3 Hematologic Malignancies

By Lisa A. Raedler, PhD, RPh

December 2014, Vol 4, No 8

Beleodaq (Belinostat) Receives FDA Approval for the Treatment of Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma

By Lisa A. Raedler, PhD, RPh

November 2014, Vol 4, No 7

Arzerra (Ofatumumab) Receives FDA Approval for Patients with Previously Untreated Chronic Lymphocytic Leukemia for Use in Combination with Chlorambucil

By Lisa A. Raedler, PhD, RPh

October 2014, Vol 4, No 6

Zykadia (Ceritinib) Approved for the Treatment of Patients with Crizotinib-Resistant ALK-Positive Non–Small-Cell Lung Cancer

By Lisa A. Raedler, PhD, RPh

August 2014, Vol 4, No 5

Imbruvica (Ibrutinib) the First Bruton’s Tyrosine Kinase Inhibitor Approved for the Treatment of Patients with Relapsed Chronic Lymphocytic Leukemia

By Lisa A. Raedler, PhD, RPh

June 2014, Vol 4, No 4

Page 4 of 4